Analyst Ratings for Dicerna Pharmaceuticals (DRNA)

DRNA Rating Summary

  |   Expand Research on DRNA
Overall Rating: NEUTRAL   Rating Trend: =   Avg. $ Target: N/A
Rating Score: 3.8 / 10   Percentile Rank: 43%
Date Firm Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
12/9/2021 Chardan Keay Nakae Downgrade Neutral
(Buy)		 38.25
(N/A)		 38.16
(38.22)		 0.16% Details
11/19/2021 RBC Capital Luca Issi Downgrade Sector Perform
(Outperform)		 38.25
(30.00)		 21.28
(38.22)		 79.61% Details